Tech Company Financing Transactions

Silverback Therapeutics Funding Round

Silverback Therapeutics, operating out of Seattle, secured $85 million in funding from EcoR1 Capital Management, Boxer Capital and Fidelity Management & Research Company.

Transaction Overview

Company Name
Silverback Therapeutics
Announced On
9/24/2020
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series C
Investors

EcoR1 Capital Management (Lead Investor) (Scott Platshon)

Boxer Capital

Fidelity Management & Research Company

Hunt Technology Ventures

Nantahala Capital Management

Nextech Invest (Thilo Schroeder)

OrbiMed

Pontifax Fund

RA Capital

U.S. Venture Partners (Jonathan Root)

Proceeds Purpose
Silverback intends to use the proceeds to support its clinical development of SBT6050, a TLR8 agonist conjugated to a HER2-directed antibody currently in a Phase 1 clinical study for the treatment of HER2-expressing solid tumors, and to advance its robust pipeline of other ImmunoTAC therapeutics.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
500 Fairview Ave. N 600
Seattle, WA 98109
USA
Phone
(206) 456-2900
Website
www.silverbacktx.com
Email Address
[email protected]
Overview
Silverback Therapeutics (Nasdaq: SBTX) is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness -- until now.
Profile
Silverback Therapeutics LinkedIn Company Profile
Social Media
Silverback Therapeutics Company Twitter Account
Company News
Silverback Therapeutics News
Facebook
Silverback Therapeutics on Facebook
YouTube
Silverback Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Laura Shawver
  Laura Shawver LinkedIn Profile  Laura Shawver Twitter Account  Laura Shawver News  Laura Shawver on Facebook
Chief Medical Officer
Naomi Hunder
  Naomi Hunder LinkedIn Profile  Naomi Hunder Twitter Account  Naomi Hunder News  Naomi Hunder on Facebook
Chief Scientific Officer
Valerie Odegard
  Valerie Odegard LinkedIn Profile  Valerie Odegard Twitter Account  Valerie Odegard News  Valerie Odegard on Facebook
Founder
Peter Thompson
  Peter Thompson LinkedIn Profile  Peter Thompson Twitter Account  Peter Thompson News  Peter Thompson on Facebook
Vice President
Sateesh Natarajan
  Sateesh Natarajan LinkedIn Profile  Sateesh Natarajan Twitter Account  Sateesh Natarajan News  Sateesh Natarajan on Facebook
VP - Finance
Russ Hawkinson
  Russ Hawkinson LinkedIn Profile  Russ Hawkinson Twitter Account  Russ Hawkinson News  Russ Hawkinson on Facebook
VP - General Counsel
Jeffrey Pepe
  Jeffrey Pepe LinkedIn Profile  Jeffrey Pepe Twitter Account  Jeffrey Pepe News  Jeffrey Pepe on Facebook
VP - Operations
Patricia Leith
  Patricia Leith LinkedIn Profile  Patricia Leith Twitter Account  Patricia Leith News  Patricia Leith on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/23/2020: Art of Sport venture capital transaction
Next: 9/24/2020: Libra Therapeutics venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.